Biology subjects

Garraway, L.

Publications and source records attributed to Garraway, L..

6 recordsLinked to original sources

bioRxiv2026

Archetype analysis of multiplexed antibody imaging reveals interpretable morphological programs in optical pooled screens

High-content imaging-based screens with small molecule or genetic perturbations rely on rich optical phenotypes, yet how distinct subcellular markers contribute complementary biological information remains unclear. Here, we introduce CellMAPP, a multiplexed organelle imaging platform that uses optical pooled screens with iterative antibody staining to map cellular architecture under perturbation. Using 17 markers across 524 genetic perturbations in MCF-7 cells, we systematically examined how individual, and combinations of, markers capture diverse morphological responses. We find that markers provide complementary views of perturbation effects, with increased multiplexing improving signal and the breadth of hit recovery, although some phenotypes are better recovered from a subset of features rather than a full profile. Because non-molecular image-based profiles can be challenging to link with interpretable biology, we developed CHART (available at https://github.com/Genentech/CHART), an archetype analysis framework that identifies distinct reference morphological states for each marker and uses multimodal large language models (MLLMs) to automatically annotate them, connecting cellular images to recognizable organelle phenotypes. Integrating archetypes across multiple markers revealed modular morphological programs that describe coordinated organelle reorganization in response to perturbation. This framework identified regulators of defined organelle states such as micronuclei, nominated novel gene functions and revealed complex patterns of multi-organelle reposition. Together, optical profiling with MAPP and CHART provides an interpretable, scalable framework for image-based screens that sheds light on rules governing cellular structural reprogramming.

systems biology↗

bioRxiv2026

Scalable multimodal mapping of macrophage regulatory architecture by integrating optical and transcriptomic pooled screens

Understanding how genetic perturbations reshape cellular states requires measuring diverse phenotypic modalities at scale. Here, we present PerturbPair, a platform that combines parallel Perturb-Seq and optical pooled screening (OPS) in primary mouse bone marrow-derived macrophages stimulated with lipopolysaccharide. Profiling over 334,000 single-cell transcriptomes across [~]1,000 gene perturbations and 7.8 million imaging-phenotyped cells across [~]3,000 gene perturbations, we reveal high concordance between transcriptomic and optical perturbation signatures. While RNA and imaging phenotypes were broadly concordant, OPS demonstrated superior sensitivity for weak-effect perturbations owing to greater cell throughput, and captured post-transcriptional regulatory events--such as protein trapping and mTOR-dependent phosphorylation--that left no detectable transcriptional footprint. To exploit cross-modal relationships, we developed EB-MoCAVI, an empirical Bayesian variational inference framework that both imputes RNA profiles for perturbations measured only by imaging--effectively tripling our Perturb-Seq dataset in silico--and denoises transcriptomic estimates for perturbations with sparse cell coverage by leveraging matched imaging data as a regularizer. A secondary screen validated the imputed transcriptional profiles and corroborated the cytosolic iron-sulfur assembly pathway as a candidate restraint on macrophage interferon tone. Integrating measured and imputed profiles with rare-variant burden statistics from the UK Biobank identified disease-specific macrophage gene programs and causal regulatory nodes for monocyte counts, type 2 diabetes, and inflammatory bowel disease. PerturbPair establishes a generalizable framework for multimodal perturbation atlases, pointing toward quantitative, causally-informed cross-modal models of cellular behavior.

genomics↗

bioRxiv2023

Highly multiplexed, image-based pooled screens in primary cells and tissues with PerturbView

Optical pooled screening (OPS) is a highly scalable method for linking image-based phenotypes with cellular perturbations. However, it has thus far been restricted to relatively low-plex phenotypic readouts in cancer cell lines in culture, due to limitations associated with in situ sequencing (ISS) of perturbation barcodes. Here, we developed PerturbView, an OPS technology that leverages in vitro transcription (IVT) to amplify barcodes prior to ISS, enabling screens with highly multiplexed phenotypic readouts across diverse systems, including primary cells and tissues. We demonstrate PerturbView in iPSC-derived neurons, primary immune cells, and tumor tissue sections from animal models. In a screen of immune signaling pathways in primary bone marrow-derived macrophages, PerturbView uncovered both known and novel regulators of NF{kappa}B signaling. Furthermore, we combined PerturbView with spatial transcriptomics in tissue sections from a mouse xenograft model, paving the way to in vivo screens with rich optical and transcriptomic phenotypes. PerturbView broadens the scope of OPS to a wide range of models and applications.

systems biology↗

bioRxiv2023

A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancer

Chromosomal gains are among the most frequent somatic genetic alterations occurring in cancer. While the effect of sustained oncogene expression has been characterized, the impact of copy-number gains affecting collaterally-amplified "bystander" genes on cellular fitness remains less understood. To investigate this, we built a comprehensive map of dosage compensations across human cancers by integrating expression and copy number profiles from over 8,000 TCGA tumors and CCLE cell lines. Further, we analyzed the effect of gene overexpression across 17 human cancer ORF screens to provide an overview of genes that prove toxic to cancer cells when overexpressed. Combining these two independent approaches we propose a class of Amplification-Related Gain Of Sensitivity (ARGOS) genes. These genes are located in commonly amplified regions of the genome, have lower expression levels than expected by their copy-number status, and are toxic to cancer cells when overexpressed. We experimentally validated CDKN1A and RBM14 as high-confidence pan-cancer ARGOS genes in lung and breast cancer cell line models. We additionally suggest that RBM14s mechanism of toxicity involves altered DNA damage response and innate immune signaling processes following gene overexpression. Finally, we provide a comprehensive catalog of compensated, toxic, and ARGOS genes as a community resource.

cancer biology↗

bioRxiv2018

6-Phosphogluconate Dehydrogenase Links Cytosolic Carbohydrate Metabolism to Protein Secretion

The proteinaceous extracellular matrix (ECM) is vital for cancer cell survival, proliferation, migration, and differentiation. However, little is known regarding metabolic pathways required in the ECM secretion process. By using an unbiased computational approach, we searched for enzymes whose suppression may lead to disruptions in protein secretion. Here, we show that 6-phosphogluconate dehydrogenase (PGD), a cytosolic enzyme involved in carbohydrate metabolism, is required for endoplasmic reticulum (ER) structural integrity and protein secretion. Chemical inhibition or genetic suppression of its activity led to cell stress accompanied by significantly expanded ER volume and can be rescued by compensating glutathione supplies. Our results also suggest that this characteristic ER-dilation phenotype may be a general marker indicating increased ECM protein congestion inside cells and decreased secretion. Thus, PGD exemplifies a nexus of cytosolic carbohydrate metabolism and protein secretion.

biochemistry↗

bioRxiv2018

Inherited DNA Repair Defects in Colorectal Cancer

Colorectal cancer (CRC) heritability has been estimated to be around 30%. However, mutations in the known CRC susceptibility genes explain CRC risk in under 10% of the cases. Germline mutations in DNA-repair genes (DRGs) have recently been reported in CRC but their contribution to CRC risk is largely unknown. We evaluated the gene-level germline mutation enrichment of 40 DRGs in 680 unselected CRC individuals compared to 27728 ancestry-matched cancer-free adults. Significant findings were then examined in independent cohorts of 1661 unselected CRC cases and 1456 early-onset CRC cases. Of 680 individuals in the discovery set, 31 (4.56%) individuals harbored germline pathogenic mutations in known CRC susceptibility genes while another 33 (4.85%) individuals had DRG mutations that have not been previously associated with CRC risk. Germline pathogenic mutations in ATM and PALB2 were enriched in both the discovery (OR= 2.81; P= 0.035 and OR= 4.91; P= 0.024, respectively) and validation sets (OR= 2.97; Adjusted P= 0.0013 and OR= 3.42; Adjusted P= 0.034, for ATM and PALB2 respectively). Biallelic loss of ATM was evident in all cases with matched tumor profiling. CRC cases also had higher rates of actionable mutations in the HR pathway that can substantially increase the risk of developing cancers other than CRC. Our analysis provides evidence for ATM and PALB2 as CRC risk genes, underscoring the importance of the homologous recombination pathway in CRC. In addition, we identified frequent complete homologous recombination deficiency in CRC tumors, representing a unique opportunity to explore targeted therapeutic interventions such as PARPi.

genetics↗